{
  "source": "PA-Med-Nec-Furoscix.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2299-4\nProgram Prior Authorization/Medical Necessity\nMedication Furoscix® (furosemide injection)\nP&T Approval Date 3/2023, 3/2024, 10/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nFuroscix (furosemide injection) is a loop diuretic indicated for the treatment of edema\nin adult patients with chronic heart failure or chronic kidney disease, including the nephrotic\nsyndrome.\n2. Coverage Criteria a:\nA. Authorization\n1. Furoscix will be approved based on all of the following criteria:\na. One of the following:\n(1) Diagnosis of chronic heart failure\n(2) Diagnosis of chronic kidney disease (CKD)\n-AND-\nb. Submission of medical records confirming that the patient is established on\nbackground loop diuretic therapy (e.g., bumetanide, furosemide, torsemide) for\nthe treatment of edema\n-AND-\nc. Both of the following:\n(1) Patient does not require ongoing emergency care or hospitalization\n-AND-\n(2) Patient is currently a candidate for parenteral diuresis outside of the hospital\n-AND-\nd. Furoscix is prescribed by or in consultation with one of the following:\n(1) cardiologist\n(2) nephrologist\nAuthorization will be issued for 1 month\n© 2025 UnitedHealthcare Services, Inc.\n1\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply Limits may be in place.\n4. References:\n1. Furoscix [package insert]. Burlington, MA: scPharmaceuticals, Inc.; March 2025.\n2. Heidenreich PA, Bozkurt, B, et al. 2022 AHA/ACC/HFSA Guideline for the Management of\nHea",
    " in place.\n4. References:\n1. Furoscix [package insert]. Burlington, MA: scPharmaceuticals, Inc.; March 2025.\n2. Heidenreich PA, Bozkurt, B, et al. 2022 AHA/ACC/HFSA Guideline for the Management of\nHeart Failure: A Report of the American College of Cardiology/American Heart Association\nJoint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032.\nProgram Prior Authorization/Medical Necessity - Furoscix (furosemide injection)\nChange Control\n3/2023 New program.\n3/2024 Annual review. Updated background to include limitations of use.\nUpdated reference.\n10/2024 Updated background and removed criteria for NYHA Class II and Class\nIII chronic heart failure per updated indication that includes NYHA Class\nIV chronic heart failure. Updated references.\n5/2025 Updated background and added criteria for CKD per updated indication.\nRemoved creatinine clearance requirements. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}